Oxygen Saturation in Hospitalized COVID-19 Patients and Its Relation to Colchicine Treatment: A Retrospective Cohort Study with an Updated Systematic Review DOI Creative Commons
Sandy Sharaf, Rasha Ashmawy, Eman Saadi Saleh

et al.

Medicina, Journal Year: 2023, Volume and Issue: 59(5), P. 934 - 934

Published: May 12, 2023

Background: Colchicine has been proposed as a cytokine storm-blocking agent for COVID-19 due to its efficacy an anti-inflammatory drug. The findings of the studies were contentious on role colchicine in preventing deterioration patients. We aimed evaluate COVID-19-hospitalized Design: A retrospective observational cohort study was carried out at three major isolation hospitals Alexandria (Egypt), covering multiple centers. In addition, systematic review conducted by searching six different databases published utilization patients with until March 2023. primary outcome measure determine whether could decrease number days that patient needed supplemental oxygen. secondary outcomes reduce hospitalization and mortality rate these Results: Out 515 hospitalized patients, 411 included survival analysis. After adjusting patients’ characteristics, not receiving had shorter length stay (median: 7.0 vs. 6.0 days) fewer oxygen treatment 5.0 days), p < 0.05, but there no significant difference rate. subgroup analysis based equipment admission, admitted nasal cannula/face masks who did receive duration supply than those [Hazard Ratio (HR) = 0.76 (CI 0.59–0.97)]. Using cox-regression analysis, clarithromycin compared azithromycin colchicine-treated associated higher risk longer [HR 1.77 1.04–2.99)]. Furthermore, we summarized 36 studies, including 114,878 Conclusions: given poorer terms use their hospital stay. Therefore, findings, is recommended adults.

Language: Английский

Effect of dapagliflozin on COVID-19 infection and risk of hospitalization DOI Creative Commons
Ángel Salgado‐Barreira, José Seijas‐Amigo, Moisés Rodríguez‐Mañero

et al.

Journal of Antimicrobial Chemotherapy, Journal Year: 2023, Volume and Issue: 78(9), P. 2335 - 2342

Published: July 23, 2023

Dapagliflozin has been proposed as a potential treatment for coronavirus disease 2019 (COVID-19) by reducing cytokine production and inflammation. However, there are limited data on its effectiveness. We aimed to evaluate the impact of dapagliflozin COVID-19 severity (including hospitalization risk, ICU admission, in-hospital death progression severe COVID-19) susceptibility infection.We conducted population-based case-control study. For aim 1, we assessed in cases (positive PCR patients requiring hospitalization) matched controls (negative or positive not hospitalization). 2, compared (hospitalized non-hospitalized) with controls. Adjusted odds ratios (aORs) were calculated using generalized linear mixed model.We analysed 86 602 subjects: 3060 hospitalized cases, 26 757 non-hospitalized 56 785 Among patients, 228 admitted 413 died. had no effect risk (aOR 0.98; 95% CI 0.65-1.48; P = 0.915), admissions 1.21; 0.34-4.25; 0.767) 1.33; 0.53-3.30; 0.543). reduced 35%, but this was statistically significant 0.65; 0.40-1.06; 0.086). associated 30% increased infection 1.31; 1.05-1.62; 0.015).Use prior SARS-CoV-2 an hospitalization, mortality COVID-19. it infection.

Language: Английский

Citations

5
Colchicine and risk of hospitalization due to COVID‐19: A population‐based study DOI Creative Commons

María Sáenz‐Aldea,

Ángel Salgado‐Barreira, Margarita Taracido

et al.

Journal of Medical Virology, Journal Year: 2023, Volume and Issue: 95(2)

Published: Jan. 14, 2023

Abstract Colchicine is one of the most widely studied and best‐known anti‐inflammatory treatments. This study aimed to assess effect colchicine on risk hospitalization due COVID‐19; its susceptibility severity virus in patients with COVID‐19. We carried out a population‐based case‐control study. The following groups were applied: (1) , cases positive PCR who hospitalized COVID‐19, controls without PCR; (2) (hospitalized non‐hospitalized), same controls; (3) determine potential subjects COVID‐19 hospitalized, nonhospitalised. Different electronic, linked, administrative health clinical databases used extract data sociodemographic variables, comorbidities, medications dispensed. covered 3060 26 757 not 56 785 healthy controls. After adjustment for comorbidities other treatments, did modify (adjusted odd ratio [OR] 1.08 [95% confidence interval (CI) 0.76−1.53]), patients' contracting disease OR 1.12 (95% CI 0.91−1.37)) or infection 1.03 0.67−1.59]). Our results would neither support prophylactic use prevention any type patient, nor justify withdrawal treatment higher

Language: Английский

Citations

4
Colchicine and risk of COVID‐19‐associated hospitalization DOI

Hui‐Chin Chang,

Shuo‐Yan Gau

Journal of Medical Virology, Journal Year: 2023, Volume and Issue: 95(3)

Published: March 1, 2023

Language: Английский

Citations

1
Oxygen Saturation in Hospitalized COVID-19 Patients and Its Relation to Colchicine Treatment: A Retrospective Cohort Study with an Updated Systematic Review DOI Creative Commons
Sandy Sharaf, Rasha Ashmawy, Eman Saadi Saleh

et al.

Medicina, Journal Year: 2023, Volume and Issue: 59(5), P. 934 - 934

Published: May 12, 2023

Background: Colchicine has been proposed as a cytokine storm-blocking agent for COVID-19 due to its efficacy an anti-inflammatory drug. The findings of the studies were contentious on role colchicine in preventing deterioration patients. We aimed evaluate COVID-19-hospitalized Design: A retrospective observational cohort study was carried out at three major isolation hospitals Alexandria (Egypt), covering multiple centers. In addition, systematic review conducted by searching six different databases published utilization patients with until March 2023. primary outcome measure determine whether could decrease number days that patient needed supplemental oxygen. secondary outcomes reduce hospitalization and mortality rate these Results: Out 515 hospitalized patients, 411 included survival analysis. After adjusting patients’ characteristics, not receiving had shorter length stay (median: 7.0 vs. 6.0 days) fewer oxygen treatment 5.0 days), p < 0.05, but there no significant difference rate. subgroup analysis based equipment admission, admitted nasal cannula/face masks who did receive duration supply than those [Hazard Ratio (HR) = 0.76 (CI 0.59–0.97)]. Using cox-regression analysis, clarithromycin compared azithromycin colchicine-treated associated higher risk longer [HR 1.77 1.04–2.99)]. Furthermore, we summarized 36 studies, including 114,878 Conclusions: given poorer terms use their hospital stay. Therefore, findings, is recommended adults.

Language: Английский

Citations

1